Is blue dye still required during sentinel lymph node biopsy for breast cancer?

Peek, MC, Kovacs, T, Baker, RD ORCID: https://orcid.org/0000-0003-3555-3425, Hamed, H, Kothari, A and Douek, M 2016, 'Is blue dye still required during sentinel lymph node biopsy for breast cancer?' , ecancermedicalscience, 10 .

Preview

PDF - Published Version Available under License Creative Commons Attribution. Download (252kB) | Preview

Abstract

BACKGROUND: In early breast cancer, the optimal technique for sentinel lymph node biopsy (SLNB) is the combined technique (radioisotope and Patent Blue V) which achieves high identification rates. Despite this, many centres have decided to stop using blue dye due to blue-dye-related complications (tattoo, anaphylaxis). We evaluated the SLNB identification rate using the combined technique with and without Patent Blue V and the blue-dye-related complication rates. METHODS: Clinical and histological data were analysed on patients undergoing SLNB between March 2014 and April 2015. SLNB was performed following standard hospital protocols using the combined technique. RESULTS: A total of 208 patients underwent SLNB and 160 patients (342 nodes) with complete operation notes were available for final analysis. The identification rate with the combined technique was 98.8% (n = 158/160), with blue dye alone 92.5% (n = 148/160) and with radioisotope alone 97.5% (n = 156/160). A total of 76.9% (263/342) of nodes were radioactive and blue, 15.5% (53/342) only radioactive and 2.3% (8/342) only blue, 5.3% (18/342) were neither radioactive nor blue. No anaphylactic reactions were reported and blue skin staining was reported in six (3.8%) patients. CONCLUSION: The combined technique should continue be the preferred technique for SLNB and should be standardised. Radioisotope alone (but not blue dye alone) has comparable sentinel node identification rates in experienced hands. National guidelines are required to optimise operative documentation.

Item Type:	Article
Schools:	Schools > Salford Business School
Journal or Publication Title:	ecancermedicalscience
Publisher:	Cancer Intelligence
ISSN:	1754-6605
Funders:	Colonis Pharma
Depositing User:	Prof Rose Dawn Baker
Date Deposited:	31 Jan 2017 15:55
Last Modified:	15 Feb 2022 21:39
URI:	https://usir.salford.ac.uk/id/eprint/41275

Actions (login required)

Edit record (repository staff only)